Abstract Search

ea0099p471 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients with HbA1c 9%-11%

Kurmi Prakash , Singh Manish , Gupta Vishal , Siddegowda Chikkalingaiah , Shukla Jitendra , Gofne Sandip , Lomte Nilesh , Shendkar Kaustubh , Gangwani Dinesh , Kumar Surendra , Gupta Sandeep , G Nagarajaiah Aravind , Bhaskar Amit , Sharma Prabhat , Baidya Arjun , Maiti Animesh , Gowda Ambana , Ambaliya Jayesh , Giriappa K Balachandra , Mahavar Sunil , Gupta Hemant , Mandodari Rajurkar Dr , Sonowal Supriya , Patel Piyush , Patil Dipak , Lakhwani Lalit , Ghadge Pravin , Mehta Suyog , Joglekar Sadhna

Background and Objective: Fixed-dose combination (FDC) of dapagliflozin+metformin+sulfonylurea with complementary mechanisms can provide effective glycaemic control, preserve beta-cell function, improved compliance without risk of weight gain, and reno-protective action in type 2 diabetes mellitus (T2DM) patients. This subgroup analysis aimed to assess efficacy and safety of triple-drug FDC versus (vs) two-drug combination in T2DM Indian patients with HbA1c 9%-11%.<p class...

0 shares

ea0099ep337 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients aged <45 years and 45 to 65 years

Kurmi Prakash , Singh Manish , Gupta Vishal , Siddegowda Chikkalingaiah , Shukla Jitendra , Gofne Sandip , Lomte Nilesh , Shendkar Kaustubh , Gangwani Dinesh , Kumar Surendra , Gupta Sandeep , G Nagarajaiah Aravind , Bhaskar Amit , Sharma Prabhat , Baidya Arjun , Maiti Animesh , Gowda Ambana , Ambaliya Jayesh , Giriappa K Balachandra , Mahavar Sunil , Gupta Hemant , Rajurkar Mandodari , Sonowal Supriya , Patel Piyush , Patil Dipak , Lakhwani Lalit , Ghadge Pravin , Mehta Suyog , Joglekar Sadhna

Background and Objective: Fixed-dose combination (FDC) of dapagliflozin+metformin+sulfonylurea with complementary mechanisms can provide effective glycaemic control, preserve beta-cell function, improved compliance without risk of weight gain, and reno-protective action in type 2 diabetes mellitus (T2DM) patients. This subgroup analysis assessed efficacy and safety of triple-drug FDC vs (vs) two-drug combination in T2DM Indian patients aged <45 years and 45-65 years.<p...

0 shares

Endocrine Abstracts

Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients with HbA1c 9%-11%

Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients aged <45 years and 45 to 65 years

BiosciAbstracts